Effects of long-term low-dose mifepristone on reproductive function in women

H. B. Croxatto, L. Kovács, R. Massai, B. A. Resch, B. Fuentealba, A. M. Salvatierra, H. D. Croxatto, S. Zalányi, S. Viski, L. Krenács

Resultado de la investigación: Article

59 Citas (Scopus)

Resumen

Low-dose antiprogestin administration has been proposed as a new contraceptive modality to interference with endometrial receptivity without disturbing ovarian function. The effects of 1 mg/day mifepristone for 150 days on the menstrual cycle were assessed in 21 surgically sterilized women. The aim was to study each woman for one control cycle and during months 1, 3 and 5 of treatment. Ovulation, endometrial thickness, serum oestradiol and progesterone, urinary luteinizing hormone, endometrial morphology and cervical mucus were assessed. Luteal phase progesterone concentrations were observed in 36 of the 60 treated months assessed and less frequently as treatment progressed. The bleeding pattern was regular in most biphasic cycles, while prolonged interbleeding intervals or no bleeding were associated with monophasic cycles. Altered endometrial morphology was found in all cases irrespective of the occurrence of luteal activity. Increased endometrial thickness and dilated glands were observed in 25 and 34% respectively of the monophasic cycles. Mifepristone, 1 mg/day, interferes with endometrial development while allowing the occurrence of biphasic ovarian cycles and regular bleeding. However, it also prevents ovarian cyclicity in a high proportion of treated months, and this is associated with increased endometrial growth in some women, which may be of concern.

Idioma originalEnglish
Páginas (desde-hasta)793-798
Número de páginas6
PublicaciónHuman Reproduction
Volumen13
N.º4
DOI
EstadoPublished - 1998

Huella dactilar

Mifepristone
Menstrual Cycle
Hemorrhage
Progesterone
Cervix Mucus
Luteal Phase
Corpus Luteum
Periodicity
Luteinizing Hormone
Contraceptive Agents
Ovulation
Estradiol
Therapeutics
Growth
Serum

ASJC Scopus subject areas

  • Reproductive Medicine
  • Rehabilitation
  • Obstetrics and Gynaecology

Citar esto

Croxatto, H. B., Kovács, L., Massai, R., Resch, B. A., Fuentealba, B., Salvatierra, A. M., ... Krenács, L. (1998). Effects of long-term low-dose mifepristone on reproductive function in women. Human Reproduction, 13(4), 793-798. https://doi.org/10.1093/humrep/13.4.793
Croxatto, H. B. ; Kovács, L. ; Massai, R. ; Resch, B. A. ; Fuentealba, B. ; Salvatierra, A. M. ; Croxatto, H. D. ; Zalányi, S. ; Viski, S. ; Krenács, L. / Effects of long-term low-dose mifepristone on reproductive function in women. En: Human Reproduction. 1998 ; Vol. 13, N.º 4. pp. 793-798.
@article{6fa8e10e66374384bd2c61c2c89dc631,
title = "Effects of long-term low-dose mifepristone on reproductive function in women",
abstract = "Low-dose antiprogestin administration has been proposed as a new contraceptive modality to interference with endometrial receptivity without disturbing ovarian function. The effects of 1 mg/day mifepristone for 150 days on the menstrual cycle were assessed in 21 surgically sterilized women. The aim was to study each woman for one control cycle and during months 1, 3 and 5 of treatment. Ovulation, endometrial thickness, serum oestradiol and progesterone, urinary luteinizing hormone, endometrial morphology and cervical mucus were assessed. Luteal phase progesterone concentrations were observed in 36 of the 60 treated months assessed and less frequently as treatment progressed. The bleeding pattern was regular in most biphasic cycles, while prolonged interbleeding intervals or no bleeding were associated with monophasic cycles. Altered endometrial morphology was found in all cases irrespective of the occurrence of luteal activity. Increased endometrial thickness and dilated glands were observed in 25 and 34{\%} respectively of the monophasic cycles. Mifepristone, 1 mg/day, interferes with endometrial development while allowing the occurrence of biphasic ovarian cycles and regular bleeding. However, it also prevents ovarian cyclicity in a high proportion of treated months, and this is associated with increased endometrial growth in some women, which may be of concern.",
keywords = "Antiprogestin, Endometrial contraception, Mifepristone, Ovarian cycle, Women",
author = "Croxatto, {H. B.} and L. Kov{\'a}cs and R. Massai and Resch, {B. A.} and B. Fuentealba and Salvatierra, {A. M.} and Croxatto, {H. D.} and S. Zal{\'a}nyi and S. Viski and L. Kren{\'a}cs",
year = "1998",
doi = "10.1093/humrep/13.4.793",
language = "English",
volume = "13",
pages = "793--798",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "4",

}

Croxatto, HB, Kovács, L, Massai, R, Resch, BA, Fuentealba, B, Salvatierra, AM, Croxatto, HD, Zalányi, S, Viski, S & Krenács, L 1998, 'Effects of long-term low-dose mifepristone on reproductive function in women', Human Reproduction, vol. 13, n.º 4, pp. 793-798. https://doi.org/10.1093/humrep/13.4.793

Effects of long-term low-dose mifepristone on reproductive function in women. / Croxatto, H. B.; Kovács, L.; Massai, R.; Resch, B. A.; Fuentealba, B.; Salvatierra, A. M.; Croxatto, H. D.; Zalányi, S.; Viski, S.; Krenács, L.

En: Human Reproduction, Vol. 13, N.º 4, 1998, p. 793-798.

Resultado de la investigación: Article

TY - JOUR

T1 - Effects of long-term low-dose mifepristone on reproductive function in women

AU - Croxatto, H. B.

AU - Kovács, L.

AU - Massai, R.

AU - Resch, B. A.

AU - Fuentealba, B.

AU - Salvatierra, A. M.

AU - Croxatto, H. D.

AU - Zalányi, S.

AU - Viski, S.

AU - Krenács, L.

PY - 1998

Y1 - 1998

N2 - Low-dose antiprogestin administration has been proposed as a new contraceptive modality to interference with endometrial receptivity without disturbing ovarian function. The effects of 1 mg/day mifepristone for 150 days on the menstrual cycle were assessed in 21 surgically sterilized women. The aim was to study each woman for one control cycle and during months 1, 3 and 5 of treatment. Ovulation, endometrial thickness, serum oestradiol and progesterone, urinary luteinizing hormone, endometrial morphology and cervical mucus were assessed. Luteal phase progesterone concentrations were observed in 36 of the 60 treated months assessed and less frequently as treatment progressed. The bleeding pattern was regular in most biphasic cycles, while prolonged interbleeding intervals or no bleeding were associated with monophasic cycles. Altered endometrial morphology was found in all cases irrespective of the occurrence of luteal activity. Increased endometrial thickness and dilated glands were observed in 25 and 34% respectively of the monophasic cycles. Mifepristone, 1 mg/day, interferes with endometrial development while allowing the occurrence of biphasic ovarian cycles and regular bleeding. However, it also prevents ovarian cyclicity in a high proportion of treated months, and this is associated with increased endometrial growth in some women, which may be of concern.

AB - Low-dose antiprogestin administration has been proposed as a new contraceptive modality to interference with endometrial receptivity without disturbing ovarian function. The effects of 1 mg/day mifepristone for 150 days on the menstrual cycle were assessed in 21 surgically sterilized women. The aim was to study each woman for one control cycle and during months 1, 3 and 5 of treatment. Ovulation, endometrial thickness, serum oestradiol and progesterone, urinary luteinizing hormone, endometrial morphology and cervical mucus were assessed. Luteal phase progesterone concentrations were observed in 36 of the 60 treated months assessed and less frequently as treatment progressed. The bleeding pattern was regular in most biphasic cycles, while prolonged interbleeding intervals or no bleeding were associated with monophasic cycles. Altered endometrial morphology was found in all cases irrespective of the occurrence of luteal activity. Increased endometrial thickness and dilated glands were observed in 25 and 34% respectively of the monophasic cycles. Mifepristone, 1 mg/day, interferes with endometrial development while allowing the occurrence of biphasic ovarian cycles and regular bleeding. However, it also prevents ovarian cyclicity in a high proportion of treated months, and this is associated with increased endometrial growth in some women, which may be of concern.

KW - Antiprogestin

KW - Endometrial contraception

KW - Mifepristone

KW - Ovarian cycle

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=2642645428&partnerID=8YFLogxK

U2 - 10.1093/humrep/13.4.793

DO - 10.1093/humrep/13.4.793

M3 - Article

C2 - 9619526

AN - SCOPUS:2642645428

VL - 13

SP - 793

EP - 798

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 4

ER -